Lexaria Bioscience (LEXX) provided an annual letter from CEO Richard Christopher, which read in part, “In 2024, Lexaria made the course ...
A diabetes drug may beat costly shots for patients with a rare genetic condition, according to a Rutgers Health study.
Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback